Vamotinib Resistance Profile Matches Second-Generation Tyrosine Kinase Inhibitors in Leukemia Study
An evaluation of vamotinib in Philadelphia chromosome–positive leukemias indicates that its resistance profile aligns with second-generation rather than third-generation tyrosine ...

